BRAF and melanoma: The first prospective evidence of vemurafenib in NSCLC came from a histology-independent phase 2 basket trial of vemurafenib, 960 mg/oral twice daily, in BRAF V600 mutation-positive non-melanoma cancers (Table 1) [40].